Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01312311

Enrollment

Registered

2011-03-10

Start date

2006-07-31

Completion date

Unknown

Last updated

2011-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Cancer

Keywords

nasopharyngeal cancer, weekly docetaxel, cisplatin

Brief summary

The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer

Interventions

DRUGDocetaxel, Cisplatin

Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* histologically confirmed nasopharyngeal cancer * chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment) * ECOG 0-1 * at least one measurable lesion

Exclusion criteria

* other cancer * pregnat * docetaxel hypersentitivity history * severe heart or pulmonary disease

Design outcomes

Primary

Measure	Time frame
objective response rate	6 months after the enrollment of the last patients

Secondary

Measure	Time frame
number of patients with adverse events	simultaneously when the analysis of primary endpoint

Countries

South Korea

Contacts

Primary ContactMyung-Ju Ahn, Pf

silkahn@skku.edu82-2-3410-3459

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026